This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
post featured image

Summer of 2022; the dawn of the behemoth, Haleon plc
By Robert Newman
Think back almost four years to December 2018. A certain Donald Trump was POTUS, Theresa May survived a vote of no confidence (by a vote...
post featured image

COVID-19; A platform for real change?
By Robert Newman
Since lockdown ensued pretty much across the Globe (as at 28 April it was estimated a third of the 7.8bn global population was under some...
post featured image

UK plays catch-up in medicinal cannabis market
By Robert Newman
1 November 2018 marks a turning point in relation to the use of medicinal cannabis in the UK. The Misuse of Drugs (Amendments) (Cannabis...
post featured image

The Biomedical Bubble debate
By Robert Newman
The FT commented earlier today on the highly provocative report "The Biomedical Bubble" published by Nesta, the charity which, in its own...
post featured image

Was the acquisition of PillPack inevitable and a sign of what is to come?
By Robert Newman
Two weeks after a certain tech giant announced its reported $1 billion acquisition of PillPack, I consider whether this move by the...
post featured image

Government must do more to implement the Life Sciences Industrial Strategy
By Robert Newman
If anyone wondered why have a two-house system of parliament, perhaps a good starting point would be to read the opinion of the Science...
post featured image

Reflecting on the Med-Tech Innovation Expo 2018
By Robert Newman
Being 'sent to Coventry' is not ordinarily something one wants to hear, but at the end of April for the last few years I have made my...
post featured image

Life after Brexit for UK science?
By Robert Newman
Reading this article by Clive Cookson at the FT, one can't help but experience differing emotions.Initially, you feel a sense of...
Load more